Capricor Therapeutics (NASDAQ: CAPR) announced that The Lancet has published positive HOPE-3 clinical trial data supporting deramiocel as a potential treatment for Duchenne muscular dystrophy (DMD). The publication in one of the world's leading medical journals strengthens the scientific evidence supporting deramiocel's potential use in treating this rare genetic disease. Sector: Biotechnology Key Highlights 📖 The Lancet published positive HOPE-3 clinical trial results 🧬 Supports deramiocel as a potential treatment for Duchenne muscular dystrophy ✅ Reinforces the therapy's clinical evidence with peer-reviewed validation 🏥 Highlights progress in developing treatments for a rare genetic disorder 📈 May support future regulatory and commercialization efforts Why It Matters Publication in The Lancet adds significant scientific credibility to Capricor's HOPE-3 results and could strengthen confidence among regulators, healthcare providers, and investors as the company advances deramiocel toward potential commercialization. https://www.thinksabio.com/reports/isr/CAPR